Clinical trials
Gastrointestinal Stromal Tumor (GIST) clinical trials
Below are recruiting gastrointestinal stromal tumor (gist) clinical trials, each written for real people, not researchers. We’re tracking 42 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06655246RecruitingPhase 1
Ziftomenib and imatinib for advanced GIST
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
Birmingham, AlabamaAges 18 years+ - NCT06926374Recruiting
Robotic surgery for gastrointestinal and urologic conditions
This trial tests a new robotic surgery system for common operations on the colon, rectum, prostate, kidney, bladder, stomach, esophagus, gallbladder, and hiatal hernia. It may offer a less invasive option for patients who need surgery for these conditions.
Hong KongAges 18–80 - NCT07072143Recruiting
Study on children with rare tumors
This study is looking at children and teens with very rare tumors to learn more about these conditions and improve future care. It aims to gather information from patients treated at participating centers.
Padova, ItalyAges birth–18 years - NCT07078136Recruiting
AI study for upper GI tumor diagnosis
This study uses artificial intelligence to help diagnose tumors in the upper stomach or esophagus. It looks at images from endoscopy and ultrasound to improve how doctors identify these growths.
Wuhan, HubeiAges 18 years+ - NCT07218926RecruitingPhase 3
New drug vs sunitinib for GIST after imatinib
This trial compares a new oral drug, IDRX-42, with the standard drug sunitinib (Sutent) for people with advanced GIST whose cancer has progressed after imatinib therapy. The goal is to see if IDRX-42 can better control the tumor growth.
Phoenix, ArizonaAges 18 years+ - NCT07379047RecruitingPhase 2/Phase 3
Testing NB003 for advanced GIST after prior treatments
This trial tests a new drug called NB003 for people with advanced GIST (a type of stomach or intestinal tumor) that has stopped responding to or could not be tolerated after standard treatments like imatinib or sunitinib. The goal is to see if NB003 can help shrink or control the tumor.
Hefei, AnhuiAges 18 years+ - NCT01416714Recruiting
Tissue sample collection during cancer surgery or biopsy
This study is collecting tissue samples from people with certain cancers while they have surgery or a biopsy. It may help researchers learn more about these cancers and improve future diagnosis and treatment.
Chicago, IllinoisAges Any age - NCT01048281Recruiting
Study of stomach and esophagus cancer samples
This study looks at stomach (gastric) and esophagus cancer, using clinical information and tissue samples. It may help researchers better understand these cancers and improve future care.
Stanford, CaliforniaAges 18 years+ - NCT07411118Recruiting
Comparing two ways to remove stomach GIST tumors with an endoscope
This trial compares two endoscopic techniques (EFTR and STER) for removing small to medium-sized GIST tumors from the stomach wall. It aims to see which method is safer and more effective.
ShanghaiAges 18–75 - NCT07434843RecruitingPhase 2
Pemigatinib for a rare type of GIST
This trial tests a drug called pemigatinib for people with a specific type of GIST (SDH-deficient GIST) that has spread or cannot be removed with surgery. The goal is to see if the drug can help stop the cancer from growing.
Boston, MassachusettsAges 18 years+ - NCT07673861Recruiting
Using ctDNA to find resistance and guide cancer treatment
This trial uses a simple blood test to look for changes in your cancer's DNA that might show why your current treatment stopped working. The results could help your doctor choose your next treatment more precisely.
LondonAges 18 years+ - NCT07559864RecruitingPhase 2
Regorafenib plus Envafolimab for treatment-resistant gastrointestinal stromal tumors
This study tests a combination of two drugs (regorafenib and envafolimab) for gastrointestinal stromal tumors (a type of stomach/bowel cancer) that have stopped responding to standard treatments. The trial compares this combination to other doctor-selected treatments to see if it slows tumor growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07581977Recruiting
A Clip Tool for Removing Small Stomach Growths
This trial tests a new two-tooth clip device designed to help doctors safely remove small gastrointestinal tumors (GISTs) from the stomach using endoscopy—a thin camera inserted through the mouth. The clip may make the removal procedure easier and safer.
BeijingAges 18–85 - NCT07550582Enrolling by invitationPhase 2
Surgery for small tumors at the food pipe opening
This trial tests a new surgical approach combining laparoscopic (minimally invasive) surgery with endoscopy (a camera procedure) to remove small tumors located where the esophagus meets the stomach. The goal is to safely remove these tumors while preserving normal function.
Beijing, Beijing MunicipalityAges 18–80 - NCT07618377RecruitingPhase 1
New Drug for Gastrointestinal Tumors After Multiple Treatments
This study tests a new drug called DCC-2618 for patients with GIST (a rare stomach/intestinal cancer) who have already tried at least three other treatments. The goal is to see if this drug can slow or shrink tumors in patients whose cancer has stopped responding to standard medications.
Kashiwa, ChibaAges 18 years+ - NCT05867901Recruiting
Test stopping imatinib early using blood DNA tests
This trial studies whether some people with high-risk GIST can safely take a “drug holiday” (pause imatinib) after surgery. They use a blood test looking for leftover cancer DNA to help decide who may benefit from stopping treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT06805825RecruitingPhase 1
Study of NN3201 for advanced cancers with c-Kit
This trial tests a new drug, NN3201, that targets a protein called c-Kit found on some cancer cells. It may be an option for people with certain advanced solid tumors, including GIST, small cell lung cancer, or other c-Kit-positive cancers, who have already tried standard treatments or cannot take them.
Ann Arbor, MichiganAges 18 years+ - NCT04181970Recruiting
Study of sarcoma care quality across Europe and Latin America
This observational study looks at information from people with sarcoma to understand how care is delivered across different centers. It does not test a new treatment, but may help improve future care and planning.
Buenos AiresAges 18–120
Hear when a new Gastrointestinal Stromal Tumor (GIST) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastrointestinal stromal tumor (gist)?
- Yes. Clin2 currently lists 42 recruiting gastrointestinal stromal tumor (gist) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastrointestinal stromal tumor (gist) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastrointestinal stromal tumor (gist) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.